<DOC>
	<DOCNO>NCT00002697</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy peripheral stem cell transplantation may kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose combination chemotherapy plus radiation therapy follow peripheral stem cell transplantation patient refractory recurrent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Followed Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy mobilization use filgrastim ( G-CSF ) without standard-dose ifosfamide , carboplatin , etoposide ( ICE ) , condition use ifosfamide etoposide plus total body irradiation high-dose ICE , autologous peripheral blood stem cell ( PBSC ) transplantation salvage therapy patient refractory , recurrent , poor prognosis non-Hodgkin 's lymphoma . - Determine efficacy reinduction comprise ICE follow autologous PBSC transplantation patient . - Determine ability standard-dose ICE combine hematopoietic growth factor mobilize PBSC patient . - Determine contamination PBSC lymphoma cell patient treated mobilization regimen . - Determine quality life patient treat regimen . OUTLINE : Patients stratify accord disease status ( relapse vs refractory ) , lymphoma grade ( low v intermediate v high ) , number extranodal sit , serum lactic dehydrogenase , performance status , age , volume disease . - Mobilization/harvest : Patients first great complete remission ( CR ) treat regimen A , whereas patient recurrent refractory disease treat regimen B . - Regimen A : Patients poor prognosis intermediate-grade lymphoma ( IGL ) first CR IGL low-grade lymphoma ( LGL ) second great CR receive mobilization filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 1-7 . Autologous peripheral blood stem cell ( PBSC ) harvest select CD34+ cell day 5 6 ( day 7 need ) . - Regimen B : Patients currently MSKCC standard dose salvage therapy protocol ifosfamide , carboplatin , etoposide ( ICE ) recurrent refractory IGL receive additional mobilization G-CSF completion last course ICE . Patients recurrent refractory IGL , immunoblastic lymphoma , LGL previously receive ifosfamide currently MSKCC standard dose salvage protocol ICE receive ifosfamide IV carboplatin day 2 etoposide IV day 1-3 ( standard-dose ICE ) follow G-CSF SC . When blood count recover , autologous PBSC harvest select CD34+ cell . - Regimens A B : If additional hematopoietic growth factor ( HGFs ) become available , may administer concurrently G-CSF . If inadequate CD34+ cell collect , autologous bone marrow harvest . - Conditioning : Patients age 60 receive dose-limiting radiotherapy treat regimen C. Patients age 60 patient age 60 receive dose-limiting radiotherapy treat regimen D. - Regimen C : Patients undergo hyperfractionated total body irradiation twice day day -10 -7 ifosfamide IV 1 hour follow etoposide IV 23 hour day -6 -2 . - Regimen D : Patients receive ifosfamide IV 1 hour , follow etoposide IV 11 hour , follow carboplatin IV 1 hour , follow etoposide IV 11 hour day -7 -3 ( high-dose ICE ) . - Regimens C D : Patients residual relapsed disease may undergo boost radiotherapy twice day , 5 day week , 1-2 week condition transplantation . - Transplantation : PBSC bone marrow reinfused day 0 . Patients receive G-CSF SC every 12 hour begin day 1 continue blood count recover . If additional HGFs become available , may administer concurrently G-CSF . Quality life assess baseline 6 , 12 , 24 month transplantation . Patients follow 1 3 month , every 3 month year 2 , every 4 month year 5 , every 6 month thereafter . PROJECTED ACCRUAL : A total 80 patient ( 20 regimen A 60 regimen B ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically proven recurrent nonHodgkin 's lymphoma Previously complete remission ( CR ) Refractory recurrent intermediategrade lymphoma ( IGL ) highgrade immunoblastic lymphoma ( IBL ) meet 1 follow condition : In partial remission ( PR ) CR currently enrol MSKCC standard dose salvage regimen ifosfamide , carboplatin , etoposide ( ICE ) In PR CR 12 salvage chemotherapy regimen ( e.g. , 3 course dexamethasone , highdose cytarabine , cisplatin ( DHAP ) ; 2 course cyclophosphamide , mechlorethamine , vincristine , procarbazine , prednisone ( CMOPP ) ) No prior ifosfamide Lowgrade lymphoma In second great remission chemosensitive relapse No HLA identical sibling donor available IGL IBL In first CR Poor prognosis , define ageadjusted international index 3 4 base lactic dehydrogenase , number extranodal sit , stage , performance status Adequate bone marrow cellularity No lymphoblastic small noncleaved cell lymphoma Ineligible total body irradiation ( TBI ) phase study prior radiotherapy dose precludes use TBI NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma.However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Physiologic 18 65 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL ( history Gilbert 's disease ) No chronic active persistent hepatitis Hepatitis B positivity allow provide follow condition meet : Bilirubin above* SGPT great 500 IU/L* Alkaline phosphatase great 2 time normal* NOTE : * In absence liver involvement lymphoma Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min No history chronic renal insufficiency Cardiovascular : LVEF least 50 % echocardiogram MUGA scan No myocardial infarction within past 6 month No unstable angina No arrhythmia chronic atrial fibrillation Pulmonary : DLCO least 50 % predict ( correct hemoglobin alveolar ventilation ) Other : HIV negative No uncontrolled infection No malignancy within past 5 year except curatively treat basal cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>